Targeted therapy of mantle cell lymphoma / 肿瘤研究与临床

ABSTRACT

Mantle cell lymphoma(MCL)is one of the most frustrating diseases because it exhibits the worst features of both aggressive non-Hodgkin Lymphoma(NHL)and indolent NHL.It develops rapidly like the former,and it is incurable and lacks of better therapeutic options like the latter.Clinical researchs confirm the activity of rituximab as a single agent and combination regimens(R-Chemo)in the treatment of MCL. Bortezomab is also active in treating patients with MCL and requires further study in combination regiments. The usages of mTOR inhibitor and radioimmunotherapy represents a novel therapeutic approaches in the treatment of MCL.It is also deserved to study.